Back to top

Analyst Blog

Theravance Inc. (THRX - Analyst Report) recently entered into an agreement with UK-based Clinigen Group plc for the commercialization of Vibativ (telavancin) in the EU and several other European countries including Switzerland and Norway.

As per the terms of the agreement, Clinigen Group will have the exclusive rights to commercialize Vibativ in the above territories for treating patients suffering from nosocomial pneumonia (NP), including ventilator-associated pneumonia, caused by susceptible isolates of gram-positive micro organisms. We note that NP is a dangerous infection and is contracted by hospitalized patients.

In return, Clinigen Group will make upfront payments of $5 million to Theravance. Additionally, Theravance will also be eligible to receive tiered royalties (in the range of 20% to 30%) on net sales of Vibativ.

Theravance received EU approval for Vibativ for NP in 2011. However, in May 2012, the European Commission (EC) suspended marketing of Vibativ due to manufacturing issues. Theravance is currently working on sorting out these issues.

Vibativ was approved by the US Food and Drug Administration (FDA) in Sep 2009 for treating adults suffering from complicated skin and skin structure infections (cSSSI) resulting from susceptible gram-positive bacteria, including both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains of staphylococcus aureus.

Theravance, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharma companies that currently look more attractive include Cytokinetics, Inc. (CYTK - Snapshot Report) and Array BioPharma Inc. (ARRY - Snapshot Report). While Cytokinetics is a Zacks Rank #1 (Strong Buy) stock, Array BioPharma carries a Zacks Rank #2 (Buy). Another pharma stock that looks attractive is Osiris Therapeutics, Inc. (OSIR - Analyst Report). Osiris is also a Zacks Rank #1 stock.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%